היקף יתרות המזומנים של החברה: Edgewise Therapeutics Inc (EWTX)

לוגו גרפי של Edgewise Therapeutics, Inc. (EWTX)

Positive results from Phase 2 trials for Duchenne muscular dystrophy are driving growth for Edgewise Therapeutics (EWTX). Edgewise Therapeutics (EWTX) is implementing ESG standards in its laboratories and adhering to testing ethics. A lack of revenue makes the business dependent on investments. The cash balance history demonstrates liquidity, where the current parameter equals 1.74, serving as a key indicator of financial stability.

EWTX - פוזיציית המזומנים של החברה Edgewise Therapeutics Inc בטווח 04.07.2022 - 21.11.2026

פילוחי מדדים ואנליטיקה של חברת Edgewise Therapeutics, Inc. (EWTX)

ניתוח בסיסי של החברה:EWTX edgewisetx.com
דוגמת מוצר של edgewisetx.com

For Edgewise Therapeutics (EWTX), which relies on grants and investments for the development of dystrophy drugs, the current cash balance serves as a critical indicator of survival until product commercialization. This metric aggregates liquid assets to assess the business's ability to meet obligations without cash flow gaps, where an excess of funds minimizes bankruptcy risks but may reduce the overall return on equity.